Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
LMWHs are widely used in diverse patient groups (renal impairment, pregnancy, obesity), but the value of anti-Xa monitoring remains unclear.
This systematic review of 48 studies (RCTs and observational) found:
- Comparable bleeding and VTE rates in monitored vs. unmonitored patients.
- Frequent dose adjustments in monitored cohorts.
- Weak or absent correlation between anti-Xa levels and clinical outcomes.
Current evidence does not support routine anti-Xa monitoring for LMWH dose adjustment.”
Read the full paper in JTH.
Article: A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
Authors: Tessa C. C. Jaspers, P. Christian Remmelzwaal, Eefje P.S. Weersink, Karina Meijer, Nakisa Khorsand
Stay updated on all science in the field of anticoagulation with Hemostasis Today.
-
Jan 20, 2026, 16:34Fernanda Orsi Explores Brazilian Registry of Thrombotic Thrombocytopenic Purpura
-
Jan 20, 2026, 16:15Tareq Abadl on Bacterial Contamination of Platelets
-
Jan 20, 2026, 15:53Ruzanna Papyan on Neuroblastoma Risk Stratification in Real-World Settings
-
Jan 20, 2026, 13:35Omar Shaltout On Stories Behind Memorable Cases
-
Jan 20, 2026, 13:25Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
-
Jan 20, 2026, 13:15Benjamin YQ Tan on Precision Lipid Management After Stroke
-
Jan 20, 2026, 13:08Antonio Paul on Blame Game in Transplantation: HLA vs Microbes
-
Jan 20, 2026, 12:33Dario Tuccinardi on Obesity as Cardiovascular Treatment Target
-
Jan 20, 2026, 12:18Ed Shovelin on CRP-A Utilization in Diverse Research Areas